RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta, Ross, Kenneth N., Moran, Teresa, Howe, Emily, Fulton, Linnea E., Mulvey, Hillary E., Bernardo, Lindsay A., Mohamoud, Farhiya, Miyoshi, Norikatsu, VanderLaan, Paul A., Costa, Daniel B., Jänne, Pasi A., Borger, Darrell R., Ramaswamy, Sridhar, Shioda, Toshi, Iafrate, Anthony J., Getz, Gad, Rudin, Charles M., Mino-Kenudson, Mari, Engelman, Jeffrey A.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Pub. Group 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4357281/
https://ncbi.nlm.nih.gov/pubmed/25758528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms7377
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados